Tumor microenvironment-driven drug resistance in urologic cancers: mechanisms and therapeutic targets
Genes & Genomics · 2026-02 · 48 (2) · 173-184
DOI: 10.1007/s13258-025-01710-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes & Genomics, online erschienen am 26.11.2025. Verfasst von Gi-Eun Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Science, Dong-A University, Busan, 49315, Korea. Hauptthemen laut MEDLINE: Tumor Microenvironment, Drug Resistance, Neoplasm, Urologic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 114 Literaturangaben. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Therapeutic resistance remains a major challenge in the management of urologic cancers, including renal cell carcinoma (RCC), bladder cancer (BC), and prostate cancer (PCa). Recent advances highlight the tumor microenvironment (TME) as a critical determinant of treatment failure across various modalities, such as androgen deprivation therapy (ADT), VEGF-targeted therapies, and immune checkpoint inhibitors (ICIs). This review summarizes how distinct TME components-such as cancer-associated fibroblasts (CAFs), extracellular matrix (ECM), immunosuppressive cells, and hypoxic conditions-promote resistance. CAFs drive oncogenic reactivation and epithelial-mesenchymal transition (EMT), while ECM stiffening hinders immune infiltration and facilitates pro-survival signaling. Immune evasion mechanisms include TGF-β-mediated T cell exclusion, regulatory T cell expansion, and adaptive checkpoint upregulation. Hypoxia and metabolic reprogramming further promote cancer stemness and immune suppression through HIF-2α activation, lactate accumulation, and acidification of TME. Targeting these resistance mechanisms requires a multifaceted approach. Promising strategies include ICI combination therapies with anti-angiogenics or TGF-β inhibitors, ECM-modulating agents, and hypoxia-targeted drugs. Novel approaches such as single-cell and spatial transcriptomics, organoid co-culture systems, and TME-derived biomarkers offer new opportunities for patient stratification and therapeutic development. Integrating TME biology into clinical practice is essential to overcome resistance and improve outcomes in urologic oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Science, Dong-A University, Busan, 49315, Korea.
- Department of Health Sciences, The Graduated of Dong-A University, Busan, 49315, Korea.
- Department of Systems Biology, Division of Basic Science, The University of Texas MD Anderson Cancer Center, Houston, TX, 77230, USA. jlee@mdanderson.org.
- Department of Biomedical Science, Dong-A University, Busan, 49315, Korea. shleem@dau.ac.kr.
- Department of Health Sciences, The Graduated of Dong-A University, Busan, 49315, Korea. shleem@dau.ac.kr.
- Department of Biochemistry, College of Oriental Medicine, Anti-Aging Research Center, Dong-Eui University, Busan, 47227, Korea. choiyh@deu.ac.kr.
ORCID-Profile: Sun-Hee Leem
Förderung
- NCI NIH HHS
Zitieren
APA
Yang, G. E., Yoon, S. Y., Lee, J. S., Leem, S. H., & Choi, Y. H. (2026). Tumor microenvironment-driven drug resistance in urologic cancers: mechanisms and therapeutic targets. Genes & Genomics, 48(2), 173-184. https://doi.org/10.1007/s13258-025-01710-2
Vancouver
Yang GE, Yoon SY, Lee JS, Leem SH, Choi YH. Tumor microenvironment-driven drug resistance in urologic cancers: mechanisms and therapeutic targets. Genes & Genomics. 2026;48(2):173-184. doi:10.1007/s13258-025-01710-2
BibTeX
@article{Yang2026,
author = {Yang, Gi-Eun and Yoon, Seo-Yeong and Lee, Ju-Seog and Leem, Sun-Hee and Choi, Yung-Hyun},
title = {Tumor microenvironment-driven drug resistance in urologic cancers: mechanisms and therapeutic targets},
journal = {Genes & Genomics},
year = {2026},
volume = {48},
number = {2},
pages = {173--184},
doi = {10.1007/s13258-025-01710-2}
}
EUVIMED